Prademagene zamikeracel (Zevaskyn) gene‑modified cellular sheets — coverage criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governs coverage and medical necessity criteria for prademagene zamikeracel (Zevaskyn) topical, gene‑modified cellular sheets for treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) and applies to Blue Cross NC members and their providers.
Added applicable revenue codes 0891 and 0892 associated with the HCPCS code(s).
Added HCPCS code J3389 (1 unit per treatment) to dosing reference table and removed C9399, J3490, and J3590 (termed 12/31/2025).
Coverage and Medical Necessity Criteria
Medical Necessity Criteria
Covered when ALL of the following are met:
medical record documentation required
medical record documentation required
medical record documentation required
3a OR 3b
- 3a: Molecular genetic testing detecting presence of biallelic mutation(s) in COL7A1 with recessive inheritance (documented)
medical record documentation required
- 3b: Confirmation that BOTH parents do NOT have any evidence of dominant disease (as alternative confirmation of recessive inheritance)
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required
medical record documentation required; duration of approval 180 days (one-time application per treatment area)
This therapy must not be used concurrently on the same treatment area with other topical or gene therapies specified in the policy. Specifically, use in combination on the same treatment area with Filsuvez (birch triterpenes), Vyjuvek (beremagene geperpavec‑svdt), or another gene therapy for the requested indication is excluded and medical record documentation confirming non‑concurrent use is required.
Treatment is considered not medically necessary when the policy criteria are not met. Examples include patients younger than 6 years, diagnoses other than RDEB, absence of molecular genetic confirmation of biallelic COL7A1 mutations (or lack of parental confirmation of recessive inheritance), wounds that do not meet the required stage (stage 2), surface area < 20 cm2, or duration < 6 months, presence or history of squamous cell carcinoma in the treatment area, active or systemic infection in the area, prior treatment of the area with the same agent, prescription without specialist involvement or consultation, or administration outside a qualified treatment center.
Billing Codes, Thresholds, and Dosing
| J3389 | HCPCS code for prademagene zamikeracel (1 unit per treatment) (per policy dosing reference) |
| 0891 | Revenue code: Special Processed Drugs - FDA Approved Cell Therapy |
| 0892 | Revenue code: Special Processed Drugs - FDA Approved Gene Therapy |
Provider Requirements, Authorization, and Denial Triggers
Prior Authorization and Dosing Limits
Prior authorization is required. Dosing must be within FDA-labeled dosing for the requested indication, and the requested quantity must not exceed the maximum units allowed per surgical session or duration of approval. Duration of approval: 180 days (6 months); one-time application per treatment area(s). Maximum units per surgical session: up to 12 cellular sheets (HCPCS J3389).
- Prior authorization required before therapy initiation
- Dose must follow FDA-labeled dosing and not exceed maximum units per surgical session (up to 12 cellular sheets)
- Duration of approval: 180 days (6 months); one-time application per treatment area(s)
- HCPCS: J3389
Step Therapy
No step therapy requirements are specified for this policy.
Required Documentation
Medical record documentation is required to support eligibility and safe use of the therapy. Documentation must be available at the time of review.
- Patient age (must be ≥ 6 years)
- Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB)
- Molecular genetic testing confirming biallelic COL7A1 mutations OR documentation confirming both parents do NOT have evidence of dominant disease
- Wound documentation: stage 2 (partial-thickness) wounds with surface area ≥ 20 cm² present ≥ 6 months
- Absence of current or prior squamous cell carcinoma in treatment area
- Absence of systemic or active infection in treatment area
- Confirmation therapy will NOT be used in combination with Filsuvez, Vyjuvek, or another gene therapy on the same area
- Prescriber specialty (dermatologist, geneticist) or documentation of specialist consultation
- Documentation that the treatment area has NOT been previously treated with the requested agent
- Treatment will be administered at a qualified treatment center (QTC)
- Requested dose and quantity documentation consistent with FDA labeling and policy limits
Triggers for Denial
Denial may be issued when required criteria or documentation are not met.
- Patient is under 6 years of age
- No diagnosis of RDEB documented
- No molecular genetic confirmation of biallelic COL7A1 mutations and insufficient parental documentation for recessive inheritance
- Wounds do not meet size, stage, or chronicity criteria (e.g., surface area < 20 cm² or present < 6 months)
- History or current evidence of squamous cell carcinoma in the treatment area
- Evidence of systemic infection or active infection in the treatment area
- Requested use in combination with Filsuvez, Vyjuvek, or another gene therapy on the same treatment area
- Prescriber is not a specialist and no specialist consultation is documented
- Requested dose or quantity exceeds FDA-labeled dosing or maximum units allowed
Clinical Background
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited blistering disorder caused by mutations in the COL7A1 gene that result in defective type VII collagen and fragile skin with chronic, non‑healing wounds. Prademagene zamikeracel (Zevaskyn) are autologous, gene‑corrected keratinocyte sheets — patient‑derived cells engineered to provide functional COL7A1 — that are applied topically as cellular sheets to treat RDEB‑associated cutaneous wounds.
Product Definitions and Supply Limits
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.